| 8.49 0.03 (0.35%) | 05-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 10.69 | 1-year : | 12.49 |
| Resists | First : | 9.15 | Second : | 10.69 |
| Pivot price | 8  |
|||
| Supports | First : | 7.91  |
Second : | 7.15 |
| MAs | MA(5) : | 8.28 |
MA(20) : | 8.18 |
| MA(100) : | 8.88 |
MA(250) : | 11.53 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 59.3 |
D(3) : | 55.8 |
| RSI | RSI(14): 56.1 |
|||
| 52-week | High : | 16.8 | Low : | 5.15 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ IMNM ] has closed below upper band by 15.6%. Bollinger Bands are 40.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 8.53 - 8.57 | 8.57 - 8.6 |
| Low: | 8.2 - 8.24 | 8.24 - 8.27 |
| Close: | 8.43 - 8.49 | 8.49 - 8.55 |
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Thu, 22 May 2025
Cancer Therapy Developer Immunome Set for TD Cowen and Goldman Sachs Healthcare Conferences - Stock Titan
Thu, 22 May 2025
Immunome to Present at Upcoming Investor Conferences - The Joplin Globe
Tue, 20 May 2025
Immunome, Inc. Reports Q1 2025 Financial Results - TipRanks
Mon, 12 May 2025
Immunome Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire
Mon, 12 May 2025
Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Thu, 08 May 2025
Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 87 (M) |
| Held by Insiders | 6.945e+007 (%) |
| Held by Institutions | 15.4 (%) |
| Shares Short | 9,520 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.5189e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 30.6 % |
| Return on Equity (ttm) | -49.4 % |
| Qtrly Rev. Growth | 9.04e+006 % |
| Gross Profit (p.s.) | -14.13 |
| Sales Per Share | -96.84 |
| EBITDA (p.s.) | -5.99502e+007 |
| Qtrly Earnings Growth | -5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -111 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.09 |
| Price to Cash Flow | 6.07 |
| Dividend | 0 |
| Forward Dividend | 1.248e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|